Funding for this research was provided by:
Women's health grant at Rambam
Article History
First Online: 3 November 2020
Declarations
:
: This manuscript was funded by the women’s health grant at Rambam.
: AR served on an advisory board for MSD, the manufacturer of pembrolizumab, and has no other conflicts of interest. TT, AA, and RP have no conflicts of interest that might be relevant to the contents of this manuscript.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: TT and RP wrote the first draft of the manuscript. All of the authors participated in the conceptual design and writing of the manuscript, as well as critical revisions of important intellectual content, while RP supervised the writing of the manuscript.